With heart health high on the agendas of manufacturers and consumers alike, Glanbia Nutritionals' interactive exhibit seeks to help attendees further their understanding of the cardiovascular benefits of ALA omega-3 from MeadowPure™ flax and the company's new patent-pending CVH47 whey peptide.
Glanbia Nutritionals will present a new granola prototype featuring SelectGrad flaxseed that harnesses all the functionality of MeadowPure™ flax, including ALA omega-3, fiber, protein and lignans, to provide anti-inflammatory and antioxidative properties. Flax experts will be on stand to also discuss the OptiSol 5000 series of flax-based functional ingredients, which offer formulation benefits such as gluten reduction.
Glanbia Nutritionals will also showcase CVH47, a new whey peptide. Recent clinical research links CVH47 with improved vascular function, associated with preventing diabetes, heart disease, obesity and hypertension. Furthermore, improved vascular function can be beneficial in maximising sports performance in athletes. At the booth, a quiz will test attendees' knowledge of the heart health benefits of ALA omega 3 and explore the importance of healthy endothelial, or blood vessel, function.
Glanbia Nutritionals is poised with the technology, the clinical backing and the development and applications expertise to help manufacturers create consumer-winning products. The team is at booth #642 to discuss how a partnership approach in new product development can add value to functional products with cardiovascular benefits.